Latest Posters

CRISPR-Cas9 gene editing using synthetic crRNA:tracrRNA or sgRNA is highly efficient and easy to use. Synthetic crRNA:tracrRNA is uniquely suited to in vitro and in vivo applications, in particular, DNA-free approach with Cas9 mRNA. Chemical synthesis of guide RNAs allows accurate and rapid production of arrayed crRNA libraries for high-confidence, loss-of-function screens.

Recognising the key challenges, we develop an end-to-end computational framework for HCA dubbed “Deep Phenotyping” that perform unsupervised analysis to leverage on the data richness for the discovery of unknown sub-phenotypes with minimal labeling cost.

In the current study we have used siRNA targeting VEGFR2 as an example to study knockdown of VEGFR2 and subsequent inhibition of tube formation by HUVECs on Growth Factor Reduced Matrigel™ in a 96-well plate format. The same strategy can be used for screening and validating siRNA based inhibitors of the angiogenic process in vitro and thus could be of utility in anti-cancer screening strategies.

The RAFT™ 3D cell culture system provides a valuable tool to investigate different cell types singularly or in co-cultures in an in-vivo like collagen based microenvironment.

This poster explains how standard analysis techniques, like fluorescence microscopy, can be applied easily to RAFT™ 3D Cell Cultures.

This poster explains how to measure cell viability easily in 3D cell cultures using the ViaLight™ Plus BioAssay.

Reported here are capabilities in automated workflows involving analytical data with chemical structures. Specifically described is automated homogenization of data from a set of instruments, including NMR structure verification, as one solution.

Modern CASE systems such as Structure Elucidator Suite provide the necessary capability to accurately elucidate a novel chemical structure for complex molecules based on readily available NMR data sets. This allows organizations to avoid expensive, labor-intensive, and time-consuming synthetic efforts.

Agilent’s Custom OneSeq provides a comprehensive, flexible, and cost-effective means to identify exon-level copy number changes as well as SNP/INDEL in one assay.

Liquid biopsy provides a circulating biomarker not only for treatment response but decision making of a sequential strategy.